The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

Cells

Francesco Strati¹  Federica Facciotti¹  Federica Perillo¹  Chiara Amoroso¹  Flavio Caprioli²  Massimo Fantini³ 

[1] Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy;Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20135 Milan, Italy;Gastroenterology Unit, Duilio Casula Hospital, AOU Cagliari, 09042 Cagliari, Italy;

关键词: inflammatory bowel diseases;    gut microbiome;    live biotherapeutic products;    FMT;   

DOI  :  10.3390/cells9051234

来源: DOAJ

【 摘 要 】

Alterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach to treat IBD patients. The customization of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics and faecal microbiota transplantation, is therefore considered to support current therapies in IBD management. In this review, we will discuss recent advancements in the understanding of host−microbe interactions in IBD and the basis to promote homeostatic immune responses through microbe-targeted therapies. By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner.

【 授权许可】

Unknown